• Olesja Parmova, Eva Vlckova, Monika Hulova, Livie Mensova, Igor Crha, Petra Stradalova, Eva Kralickova, Lenka Jurikova, Martina Podborska, Radim Mazanec, Ladislav Dusek, Jiri Jarkovsky, Josef Bednarik, Stanislav Vohanka, and Iva Srotova.
• Department of Neurology, University Hospital Brno.
• Medicine (Baltimore). 2020 Jun 5; 99 (23): e20523.

AbstractSome muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Müllerian hormone) is currently considered the best measure of ovarian reserve.A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level.The MD1 group shows a significant decrease of AMH values (median 0.7 ng/mL; range 0 - 4.9 ng/mL) compared with age-matched healthy controls (P < .01). AMH levels were similar between patients and controls in terms of females with MD2 (P = .98), FSHD (P = .55) and cDMD (P = .60).This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.

20 keywords...

hide…